Sign in Subscribe
Cancer

University of California, San Francisco Conducts Phase 1 Trial of Niraparib and Irinotecan in Cancers with Mutations in DNA Repair Genes

Strategic Insights

— 1 min read

Researchers at the University of California, San Francisco (UCSF) are leading a Phase 1 clinical trial to investigate the safety and efficacy of combining niraparib and irinotecan in treating cancers with mutations in DNA repair genes. The trial, which is currently not open for recruiting, aims to enroll 24 participants from the USA and will be conducted in collaboration with GlaxoSmithKline. The study is designed to determine whether niraparib, a PARP inhibitor, can be safely combined with irinotecan and produce manageable toxicity and reasonable efficacy.

Key Takeaways:

  • The trial's principal investigator is Pamela Munster, MD, and it is being conducted at the University of California, San Francisco.
  • The study aims to investigate the combination therapy of niraparib and irinotecan in treating cancers with mutations in DNA repair genes.
  • The trial is currently not open for recruiting, and a total of 24 participants from the USA are expected to be enrolled.
  • The study is designed to determine whether niraparib can be safely combined with irinotecan and produce manageable toxicity and reasonable efficacy.
  • The trial is being conducted in collaboration with GlaxoSmithKline.
  • Emerging evidence suggests that PARP inhibitors, such as niraparib, may be effective therapeutic strategies in a wider subset of solid tumors with defective homologous recombination (HR) or DNA repair gene mutations.
  • The study aims to build on the success of previous preclinical studies, which have demonstrated that PARP inhibitors can work as chemopotentiators.

Statistics:

  • The trial is currently not open for recruiting and will enroll a total of 24 participants from the USA.
  • The study aims to determine if niraparib and irinotecan combination therapy is safe, tolerable, and effective in treating cancers with mutations in DNA repair genes.

Sources:

  • ClinicalTrials.gov [Category: Pharmaceuticals, Drug Discovery/ Drug Development, Biotechnology, Clinical Trials]
  • Copyright 2017 Contify.com
  • NCT05694715 (https://clinicaltrials.gov/ct2/show/NCT05694715)

Read more